Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
10 2023
Historique:
received: 19 06 2023
revised: 13 08 2023
accepted: 15 08 2023
medline: 2 10 2023
pubmed: 19 8 2023
entrez: 18 8 2023
Statut: ppublish

Résumé

The RET (REarranged during Transfection) gene, which encodes for a transmembrane receptor tyrosine kinase, is an established oncogene associated with the etiology and progression of multiple types of cancer. Oncogenic RET mutations and rearrangements resulting in gene fusions have been identified in many adult cancers, including medullary and papillary thyroid cancers, lung adenocarcinomas, colon and breast cancers, and many others. While genetic RET aberrations are much less common in pediatric solid tumors, increased RET expression has been shown to be associated with poor prognosis in children with solid tumors such as neuroblastoma, prompting an interest in RET inhibition as a form of therapy for these children. A number of kinase inhibitors currently in use for patients with cancer have RET inhibitory activity, but these inhibitors also display activity against other kinases, resulting in unwanted side effects and limiting their safety and efficacy. Recent efforts have been focused on developing more specific RET inhibitors, but due to high levels of conservation between kinase binding pockets, specificity remains a drug design challenge. Here, we review the background of RET as a potential therapeutic target in neuroblastoma tumors and the results of recent preclinical studies and clinical trials evaluating the safety and efficacy of RET inhibition in adults and children. We also present a novel approach to drug discovery leveraging the chemical phenomenon of atropisomerism to develop specific RET inhibitors and present preliminary data demonstrating the efficacy of a novel RET inhibitor against neuroblastoma tumor cells.

Identifiants

pubmed: 37595672
pii: S0006-2952(23)00342-8
doi: 10.1016/j.bcp.2023.115751
pii:
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Protein-Tyrosine Kinases EC 2.7.10.1
Proto-Oncogene Proteins c-ret EC 2.7.10.1
RET protein, human EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115751

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM124637
Pays : United States

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Erica A Steen (EA)

Department of Pediatrics, Division of Hematology-Oncology, University of California San Diego, La Jolla, CA.

Mariam Basilaia (M)

Department of Chemistry and Biochemistry, San Diego State University, San Diego, CA; Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA.

William Kim (W)

Department of Medicine, University of California San Diego, La Jolla, CA.

Taelor Getz (T)

Department of Pediatrics, Division of Hematology-Oncology, University of California San Diego, La Jolla, CA.

Jeffrey L Gustafson (JL)

Department of Chemistry and Biochemistry, San Diego State University, San Diego, CA.

Peter E Zage (PE)

Department of Pediatrics, Division of Hematology-Oncology, University of California San Diego, La Jolla, CA; Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, CA. Electronic address: pzage@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH